Selective COX-2 Inhibitors: A Promise Unfulfilled?

Gastroenterology

Volumn 132, Issue 2, 2007, Pages 790-794

  Henry, David ^a   McGettigan, Patricia ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB;

ARTHRITIS; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DUODENITIS; EDITORIAL; ERADICATION THERAPY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

EID: 33847052130     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.01.017     Document Type: Editorial

References (47)

1. Gabriel S.E., Jaakkimaunen L., and Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115 (1991) 787-796
2. Langman M.J. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 84 (1988) 9-15
3. Bollini P., García Rodríguez L.A., Pérez Gutthann S., and Walker A.M. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti- inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 152 (1992) 1289-1295
4. Somerville K., Faulkner G., and Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1 (1986) 462-464
5. Kurata J.H., Elashoff J.D., and Grossman M.D. Inadequacy of the literature on the relationship between drugs ulcers and gastrointestinal bleeding. Gastroenterology 82 (1982) 373-376
6. Henry D., and Robertson J. The impact of rising use of non-steroidal anti-inflammatory drugs on peptic ulcer hospitalisation rates in New South Wales, Australia. Gastroenterology 104 (1993) 108-109
7. Griffin M.R., Piper J.M., Daugherty J.R., Snowden M., and Ray W.A. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114 (1991) 257-263
8. McManus P., Primrose J., Henry D.A., Birkett D.J., Lindner J., and Day R.O. Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. Med J Aust 164 (1996) 589-592
9. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
10. Henry D., Lim L.L., García Rodríguez L.A., Perez Gutthann S., Carson J.L., Griffin M., Savage R., Logan R., Moride Y., Hawkey C., Hill S., and Fries J.T. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312 (1996) 1563-1566
11. García Rodríguez L.A., and Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12 (2001) 570-576
12. Hooper L., Brown T.J., Elliott R.A., Payne K., Roberts C., and Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329 (2004) 948
13. Lanas A., and Hunt R. Prevention of anti-inflammatory drug-induced damage: benefits and risks of therapeutic strategies. Ann Med 38 (2006) 415-428
14. Fries J.F., Murtagh K.N., Bennett M., Zatarain E., Lingala B., and Bruce B. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50 (2004) 2433-2440
15. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
16. Langman M.J., Jensen D.M., Watson D.J., Harper S.E., Zhao P.L., Quan H., Bolognese J.A., and Simon T.J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282 (1999) 1929-1933
17. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geiss G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
18. Celebrex capsules (Celecoxib). NDA 20-998/S-009: medical officer review. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf. Accessed December 12, 2006.
19. Dequeker J., Hawkey C., Kahan A., Steinbruck K., Alegre C., Baumelou E., Begaud B., Isomaki H., Littlejohn G., Mau J., and Papazoglou S. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37 (1998) 946-951
20. Hawkey C., Kahan A., Steinbruck K., Alegre C., Baumelou E., Begaud B., Dequeker J., Isomaki H., Littlejohn G., Mau J., and Papazoglou S. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety. Br J Rheumatol 37 (1998) 937-945
21. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
22. Lisse J.R., Perlman M., Johansson G., Shoemaker J.R., Schechtman J., Skalky C.S., Dizon M.E., Polis A.B., Mollen A.J., Geba G.P., and ADVANTAGE Study Group. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 139 (2003) 539-546
23. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C.J., and TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
24. Singh G., Fort J.G., Goldstein J.L., Levy R.A., Hanrahan P.S., Bello A.E., Andrade-Ortega L., Wallemark C., Agrawal N.M., Eisen G.M., Stenson W.F., Triadafilopoulos G., and SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
25. Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A., Reicin A.S., Bombardier C., Weinblatt M.E., van der Heijde D., Erdmann E., Laine L., and MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368 (2006) 1771-1781
26. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
27. Hernández-Díaz S., Varas-Lorenzo C., and García Rodríguez L.A. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98 (2006) 266-274
28. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase-2. JAMA 296 (2006) 1633-1644
29. Lanas A., Baron J.A., Sandler R.S., Horgan K., et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132 (2007) 490-497
30. García Rodríguez L.A., and Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 (2007) 498-506
31. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T., and APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
32. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B., and PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
33. Degner F., Sigmund R., and Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther 22 (2000) 400-410
34. Garcia Rodriguez L.A., and Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12 (2001) 570-576
35. Mamdani M., Rochon P.A., Juurlink D.N., Kopp A., Anderson G.M., Naglie G., Austin P.C., and Laupacis A. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325 (2002) 624
36. MacDonald T.M., Morant S.V., Goldstein J.L., Burke T.A., and Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52 (2003) 1265-1270
37. Norgard B., Pedersen L., Johnsen S.P., Tarone R.E., McLaughlin J.K., Friis S., and Sorensen H.T. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 19 (2004) 817-825
38. Hippisley-COX J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331 (2005) 1310-1316
39. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollón F., Feu F., Gonzalez-Perez A., Zapata E., Bastida G., Rodrigo L., Santolaria S., Guell M., de Argila C.M., and Pique J.M. Asociacion Espanola de Gastroenterlogia. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Quintero E. Borda F. Gut 55 (2006) 1731-1738
40. Thomsen R.W., Riis A., Munk E.M., Nørgaard M., Christensen S., and Sørensen H.T. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: A population-based study. Am J Gastroenterol 101 (2006) 2704-2710
41. Wolfe F., Flowers N., Burke T.A., Arguelles L.M., and Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 29 (2002) 1015-1022
42. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
43. Vergara M., Catalan M., Gisbert J.P., and Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 (2005) 1411-1418
44. Chan F.K.L., Hung L.C.T., Suen B.Y., Wu J.C.Y., Lee K.C., Leung V.K.S., Hui A.J., To K.F., Leung W.K., Wong V.W.S., Chung S.C.S., and Sung J.J.Y. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
45. Weil J., Langman M.J.S., Wainwright P., Lawson D.H., Rawlins M., Logan R.F., Brown T.P., Vessey M.P., Murphy M., and Colin-Jones D.G. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46 (2000) 27-31
46. Lanas A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options Gastroenterol 9 (2006) 147-156
47. Graham D.J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 296 (2006) 1653-1656